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Abstract
Alzheimer’s disease (AD) is the most common form of
neurodegenerative dementia, affecting about 30
million people worldwide. Despite recent advances in
understanding its molecular pathology, no
mechanism-based drugs are currently available that
can halt the progression of AD. Because amyloid-b-
peptide (Ab), a primary component of senile plaques,
is thought to be a central pathogenic culprit, several
disease-modifying therapies are being developed,
including inhibitors of Ab-producing proteases and
immunotherapies with anti-Ab antibodies. Drug
repositioning or repurposing is regarded as a
complementary and reasonable approach to identify
new drug candidates for AD. This commentary will
discuss the clinical relevance of an attractive
candidate compound reported in a recent paper by
Hayes et al. (BMC Medicine 2013) as well as
perspectives regarding the possible repositioning of
oncology drugs for the treatment of AD.
See related research article here http://www.
biomedcentral.com/1741-7015/11/81
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Introduction
Alzheimer’s disease (AD) is a major type of dementia that
afflicts about 30 million people worldwide [1]. Pathologi-
cally, this disease is characterized by the presence of senile
plaques, composed primarily of amyloid b-peptide (Ab),
and neurofibrillary tangles, composed mainly of phos-
phorylated tau protein, as well as loss of synapses and neu-
rons [2]. The few drugs currently approved for clinical use,
such as donepezil, provide only symptomatic and short-
term benefits [3]. Because the accumulation of Ab, parti-
cularly the oligomeric species, appears to play a primary
pathogenic role in AD [4,5], it is a primary target for dis-
ease-modifying therapeutics of AD. Ab is generated by
serial cleavages of its precursor, amyloid precursor protein
(APP), by b-secretase (or BACE1) and g-secretase [6].
Thus, inhibitors or modulators of these proteases are
being developed. Other possible interventions include Ab
immunotherapy to promote Ab clearance and inhibition
of Ab oligomerization [3,7]. No such drugs have yet been
proven clinically effective, despite the urgent need to find
new treatments for AD. It, therefore, seems an attractive
strategy to assess the anti-Ab effects of drugs approved for
the treatment of other diseases. Such a “drug reposition-
ing” or “repurposing” approach is thought to have several
advantages, including reduced time and costs necessary
for clinical trials [8,9]. A paper by Hayes et al. published
recently in BMC Medicine [10] describes an interesting
oncology drug that may potentially be used as a disease-
modifying drug in patients with AD.
A new candidate drug for the treatment of AD
There have been several observations from multiple studies
that suggest an inverse relationship between cancer and
AD; cancer patients have been shown to have a lower risk
of developing AD, and similarly, those diagnosed with AD
seem to have a lower risk of developing cancer [11,12].
Therefore, it seemed plausible that anticancer drugs may
exert favorable effects on AD. By screening approximately
90 FDA-approved oncology drugs, a group led by Made-
palli Lakshmana found that BCNU (1,3 bis(2-chloroethyl)-
1-nitrosourea or carmustine), an alkylating agent currently
used to treat patients with brain tumors, such as malignant
gliomas, has potent activity in reducing Ab production by
cultured cells overexpressing APP [10]. Subsequent analysis
of the mechanisms by which BCNU reduces Ab produc-
tion found that BCNU increases the secretion of APPa, a
protein resulting from alternative a-cleavage of APP within
the Ab region, decreases the levels of C-terminal fragments
of APP and increases the expression of immature APP on
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the cell surface. BCNU did not directly affect the enzymatic
activities of b-, g- and a-secretases. Accordingly, BCNU
appears to reduce Ab by altering the trafficking and pro-
cessing of APP without directly affecting secretase activ-
ities. In addition, BCNU was found to increase
transforming growth factor (TGF)-b1 levels in cell media
and cell extracts, an intriguing observation in view of the
involvement of the TGF-b1 pathway in AD [13].
Following these cell-based experiments, the authors per-
formed in vivo experiments to determine whether BCNU
could reduce Ab production in a transgenic mouse model,
in which Ab plaques appear as early as six months of age.
Intraperitoneal injection of 0.5 mg/kg BCNU, a non-toxic
dose, for 60 days, from four to six months of age, resulted
in the marked reduction of Ab plaque burden in the brain.
Furthermore, BCNU treatment decreased levels of Ab and
APP C-terminal fragments and increased levels of secreted
APPa in mouse brains, recapitulating the changes
observed in cell cultures. Moreover, BCNU treatment
reduced the number of Iba1-positive microglia, indicating
that this agent suppresses microglial activation in the
mouse brain. This effect may be related to the TGF-b1
pathway, since TGF-b1 plays a constitutive role in the sup-
pression of inflammation [14]. A modest increase in astro-
glial TGF-b1 production in APP transgenic mice has been
shown to result in a significant reduction of Ab [15].
Moreover, a specific impairment of the TGF-b1 signaling
pathway has been demonstrated in the AD brain, and
TGF-b1 has been found to exert neuroprotective effects
against various insults, including Ab toxicity [13,14]. Thus,
BCNU treatment may reduce Ab production through
combined effects on APP trafficking and processing and
on the TGF-b1 pathway.
Oncology drugs have potential utility for AD
The study by Hayes et al. identified BCNU as a potential
anti-Ab drug [10]. However, several questions need to be
investigated, including whether chronic treatment with
BCNU can prevent cognitive impairment in the mouse
model and whether BCNU up-regulates TGF-b1 in vivo.
Because BCNU is metabolized very rapidly in the brain,
the authors suggested that its anti-amyloidogenic effects
may result from the action of one of its metabolites [10];
however, such a compound remains to be identified. Safety
is a major issue to be considered. For the treatment of
brain tumors, patients are implanted with BCNU wafers to
avoid systemic side effects. Although BCNU exhibited a
robust Ab-reducing effect in vivo at non-toxic concentra-
tions, the safety of long-term use has not yet been estab-
lished. If a metabolite of BCNU with a potent anti-Ab
action is identified, a safer compound with less toxicity
may be developed.
Potential AD therapy with existing oncology drugs
appears to be a promising strategy. For instance, treatment
with bexarotene, an agonist of retinoid X receptors (RXRs)
that is used to treat patients with T cell lymphoma, was
recently found to lead to pathological and behavioral
improvements in transgenic mouse models of AD [16].
Bexarotene stimulates the expression of apolipoprotein E
(ApoE) and its lipid transporters ABCA1 and ABCG1, and
facilitates Ab clearance in an ApoE dependent manner.
This agent also appears to promote microglial phagocyto-
sis. Thus, RXR agonists may be of therapeutic utility in the
treatment of AD. In addition, drugs that activate retinoic
acid receptors (RARs), such as acitretin and tamibarotene,
which are used to treat psoriasis and acute promyelocytic
leukemia, respectively, have been reported to have benefi-
cial effects on APP processing by enhancing non-amyloi-
dogenic a-secretase processing of APP, probably through
the induction of a-secretase (or ADAM10) expression
[17,18]. Because the administration of RAR agonists to
APP transgenic mice decreases Ab levels in the brain
[17,18], they are promising candidate drugs for the treat-
ment of AD. Phase II clinical trials are underway to vali-
date their clinical efficacy. Other oncology drugs with
potential utility for AD include imatinib and paclitaxel,
but both have the drawbacks of poor central nervous sys-
tem penetration [9].
Conclusions
BCNU is a unique new addition to the list of candidate
oncology drugs with potential clinical efficacy in AD.
More preclinical work, including clarification of its
mechanisms of action, is essential before BCNU proceeds
to clinical trials. Needless to say, various classes of drugs
other than those used for chemotherapy are regarded as
potential candidate drugs for AD [8,9]. Future rigorous
efforts to develop disease-modifying drugs through drug
repositioning or repurposing may lead to the emergence
of successful therapies for AD.
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